General Information
Altimmune Obesity 211
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity clinical trial.
| Protocol | ALT-801-211 |
|---|---|
| Identifier | |
| UID | cd2baed1-1aab-4b77-9cde-9db53f32828a |
| Status | Done - Archived |
| Phase | 2 |
| Category | Obesity / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2022-02-24 18:31 |
| Last Updated | 2024-01-22 22:06 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2022-08-21 | No |
| Enrollment Open | 2022-05-20 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-05-10 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2024-01-12 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Altimmune, Inc. |
|---|---|
| Division | Altimmune, Inc. |
| Team | Altimmune, Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Medpace, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
